Quick Answer
Galera Therapeutics, Inc. reported Diluted EPS of $0.64 per share for fiscal year 2025.
Galera Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.64 | +288.2% |
| 2024 | -$0.34 | +74.4% |
| 2023 | -$1.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.01 | +90.0% | — |
| June 30, 2025 | $0.00 | +100.0% | +100.0% |
| March 31, 2025 | -$0.01 | +87.5% | +90.0% |
| September 30, 2024 | -$0.10 | +69.7% | -42.9% |
| June 30, 2024 | -$0.07 | +85.4% | +12.5% |
| March 31, 2024 | -$0.08 | +84.0% | +75.8% |
| September 30, 2023 | -$0.33 | +45.0% | +31.2% |
| June 30, 2023 | -$0.48 | +11.1% | +4.0% |
- Galera Therapeutics, Inc. showed an increase of +288.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Galera Therapeutics, Inc.’s diluted eps has grown by 148.1% (from $1.33 per share (loss) to $0.64 per share).
- The most recent figure is from Galera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: